Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 366,511,264
  • Shares Outstanding, K 2,682,902
  • Annual Sales, $ 81,581 M
  • Annual Income, $ 15,297 M
  • 60-Month Beta 0.68
  • Price/Sales 4.50
  • Price/Cash Flow 12.56
  • Price/Book 6.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 2.04
  • Number of Estimates 8
  • High Estimate 2.15
  • Low Estimate 1.95
  • Prior Year 2.06
  • Growth Rate Est. (year over year) -0.97%

Price Performance

See More
Period Period Low Period High Performance
1-Month
135.39 +2.44%
on 02/27/19
140.00 -0.94%
on 03/12/19
+2.58 (+1.90%)
since 02/26/19
3-Month
123.07 +12.69%
on 12/27/18
140.00 -0.94%
on 03/12/19
+11.98 (+9.45%)
since 12/26/18
52-Week
118.62 +16.92%
on 05/29/18
148.99 -6.91%
on 12/04/18
+11.30 (+8.87%)
since 03/26/18

Most Recent Stories

More News
Janssen Submits Application for DARZALEX® (daratumumab) Combination Therapy to U.S. FDA for Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval...

JNJ : 138.75 (+1.57%)
Third Pole Therapeutics Announces Inhaled Nitric Oxide Strategic Collaboration with Actelion, a Janssen Pharmaceutical Company of Johnson & Johnson

Third Pole Therapeutics, a privately held company developing and delivering transformative cardio-pulmonary therapies, announced today that it has entered into a strategic collaboration to work with Actelion...

JNJ : 138.75 (+1.57%)
Fifth Annual Fortune 500 Employment Brand Report Published by WilsonHCG

WilsonHCG, a multi-award-winning global talent solutions provider, released its fifth annual Fortune 500 Employment Brand Report.

JNJ : 138.75 (+1.57%)
Johnson & Johnson Vision's Investigational Antihistamine-Releasing Contact Lens Demonstrates Positive Phase 3 Results

Johnson & Johnson Vision today announced that results from two Phase 3 clinical studies evaluating the company's investigational antihistamine-releasing contact lens (etafilcon A with 0.019 mg ketotifen)...

JNJ : 138.75 (+1.57%)
Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Johnson & Johnson (JNJ) closed at $136.61, marking a -0.22% move from the previous day.

JNJ : 138.75 (+1.57%)
Markets Right Now: Stock indexes end an indecisive day mixed

NEW YORK (AP) — The latest on developments in financial markets (all times local):

T : 31.30 (+1.72%)
UNP : 161.30 (-0.12%)
JNJ : 138.75 (+1.57%)
M : 24.15 (+1.22%)
VIA : 34.00 (+3.98%)
Settlement Reached Resolving Xarelto Multidistrict Litigation Claims

The makers of the popular blood thinner Xarelto® have reached a $775 million settlement to resolve litigation filed by patients who suffered a bleeding injury after taking the prescription drug.

BAYRY : 16.0800 (-0.62%)
JNJ : 138.75 (+1.57%)
J&J Files Application for Darzalex Label Expansion in Europe

J&J (JNJ) seeks an approval for Darzalex combo pertaining to the newly diagnosed, transplant-ineligible multiple myeloma patient population in the EU.

CELG : 89.35 (+1.63%)
JNJ : 138.75 (+1.57%)
RHHBY : 34.2600 (+1.27%)
BMY : 48.24 (+1.58%)
S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record at $223 Billion; 2018 Sets Record $806 Billion

S&P Dow Jones Indices ("S&P DJI") announced today that preliminary Q4 2018 S&P 500® stock buybacks, or share repurchases, set a fourth consecutive record of $223.0 billion. This displaces the previous...

GOOGL : 1,195.73 (-0.14%)
AAPL : 192.22 (+1.84%)
AVGO : 299.10 (+2.38%)
CSCO : 53.35 (+1.18%)
C : 60.80 (+0.78%)
BAC : 26.98 (+0.52%)
JPM : 99.24 (+0.31%)
JNJ : 138.75 (+1.57%)
MRK : 83.17 (+1.00%)
ORCL : 53.39 (+1.23%)
AMGN : 189.39 (+1.50%)
PFE : 42.48 (+1.41%)
MSFT : 118.01 (+0.30%)
SBUX : 72.97 (+0.93%)
IBM : 140.73 (+1.11%)
WFC : 48.57 (+1.02%)
V : 155.42 (+1.56%)
SPGI : 206.38 (+0.67%)
FB : 168.48 (+1.32%)
HD : 191.41 (+0.91%)
WMT : 98.68 (+0.52%)
Watch for Shares of Johnson&Johnson (JNJ) to Approach Support at $135.86

Shares of Johnson&Johnson (NYSE:JNJ) opened today below their pivot of $137.39 and have already reached the first level of support at $136.38. Should the shares continue to fall, the support pivots of...

JNJ : 138.75 (+1.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade JNJ with:

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

2nd Resistance Point 137.72
1st Resistance Point 137.17
Last Price 138.75
1st Support Level 135.90
2nd Support Level 135.18

See More

52-Week High 148.99
Last Price 138.75
Fibonacci 61.8% 137.39
Fibonacci 50% 133.81
Fibonacci 38.2% 130.22
52-Week Low 118.62

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar